Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012;120(25):4929-4937.

doi:10.1182/blood-2014-07-593012

Skip Nav Destination

ERRATA| September 11, 2014

Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012;120(25):4929-4937.

Blood (2014) 124 (11): 1845–1847.

https://doi.org/10.1182/blood-2014-07-593012

On pages 4930, 4931, and 4932 in the 13 December 2012 issue, there are typesetting errors in Tables 1, 2, and 3, respectively. In Tables 1, 2, and 3, two entries under the “Mean BMI at blood draw, kg/m² (SD)” heading contain typographical errors. The incorrect entries read “<18.5-25, N (%)” and “<25-30, N (%).” These two entries should have read, “18.5-<25, N (%)” and “25-<30, N (%),” respectively. The corrected Tables 1, 2, and 3 are shown.

2014

Table 1

Selected characteristics of the study population by cohort (pooled, ATBC, and HPFS)

	Pooled		ATBC³¹		HPFS³⁰
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	493	978	46	92	29	58
Mean age at blood draw, y (SD)	63.3 (7.1)	63.3 (7.2)	58.6 (4.7)	58.5 (4.7)	62.7 (9.4)	62.6 (9.5)
Sex, N (%)
Male	172 (34.9)	344 (35.2)	46 (100)	92 (100)	29 (100)	58 (100)
Female	321 (65.1)	634 (64.8)	NA	NA	NA	NA
Race, N (%)
White	432 (87.6)	860 (87.9)	46 (100)	92 (100)	26 (89.7)	55 (94.8)
Black	32 (6.5)	62 (5.3)	NA	NA	1 (3.5)	NA
Asian	12 (2.4)	25 (2.6)	NA	NA	NA	NA
Other	17 (3.4)	31 (3.2)	NA	NA	2 (6.9)	3 (5.2)
Mean BMI at blood draw, kg/m² (SD)	27.4 (5.2)	27.2 (5.0)	26.7 (2.8)	26.2 (3.8)	26.3 (3.3)	26.0 (3.2)
<18.5, N (%)	2 (0.4)	8 (0.8)	NA	NA	9 (31.0)	24 (41.4)
18.5-<25, N (%)	163 (33.1)	342 (35.0)	10 (21.7)	37 (40.2)	15 (51.7)	27 (46.6)
25-<30, N (%)	215 (43.6)	406 (41.5)	29 (63.0)	42 (45.7)	4 (13.8)	4 (6.9)
30+, N (%)	110 (22.3)	212 (21.7)	7 (15.2)	13 (14.1)	1 (3.5)	3 (5.2)
Missing, N (%)	3 (0.6)	10 (1.0)	NA	NA	NA	NA
Type of blood sample, N (%)
Serum	70 (14.2)	140 (14.3)	46 (100)	92 (100)	NA	NA
Plasma, heparin	200 (40.6)	392 (40.1)	NA	NA	NA	NA
Plasma, EDTA	202 (41.0)	404 (41.3)	NA	NA	29 (100)	58 (100)
Plasma, sodium citrate	21 (4.3)	42 (4.3)	NA	NA	NA	NA
Fasting status, N (%)
Fasting	354 (71.8)	709 (72.5)	39 (84.8)	78 (84.8)	21 (72.4)	42 (72.4)
Not fasting	139 (28.2)	269 (27.5)	7 (15.2)	14 (15.2)	8 (27.6)	16 (27.6)
Mean blood draw to diagnosis, y (range)	6.6 (0.3-18.1)	6.5 (−0.5 to 18.2)	9.8 (1.3-18.1)	9.8 (1.3-18.2)	6.6 (0.5-12.2)	6.6 (0.4-12.3)
≤3, N (%)	92 (18.7)	170 (17.9)	4 (8.7)	8 (8.7)	8 (28.6)	15 (27.3)
4-≤6, N (%)	150 (30.6)	303 (31.8)	10 (21.7)	18 (19.6)	5 (17.9)	10 (18.2)
>6, N (%)	249 (50.7)	479 (50.3)	32 (69.6)	66 (71.7)	15 (53.6)	30 (54.6)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	150 (52.5)	146.4 (49.4)	170.3 (38.7)	150.9 (44.5)	189.6 (49.2)	168.8 (46.2)
IGFBP-3, ng/mL	4 490 (1 203)	4 423 (1 170)	3 859 (941)	3 402 (1 053)	4 531 (1 110)	4 267 (991)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.2 (0.04)	0.2 (0.03)	0.2 (0.03)	0.1 (0.02)
IGFBP-1, ng/mL	32.2 (24.9)	30.3 (32.3)	21.9 (14.9)	25.2 (14.7)	34.9 (29.5)	28.8 (19.9)
C-peptide, ng/mL	2.1 (1.5)	2.1 (1.6)	1.9 (0.8)	1.7 (1.1)	2.4 (1.1)	2.6 (1.6)
CRP, mg/L	3.5 (5.6)	3.7 (5.8)	4.1 (6.8)	4.2 (8.3)	1.7 (1.6)	1.3 (1.4)
IL-6, pg/mL	2.2 (2.3)	2.5 (4.5)	3.0 (2.9)	3.7 (5.5)	1.7 (1.5)	1.5 (1.2)
sIL6R, pg/mL	41 871 (15 713)	39 278 (10 923)	36 502 (9 674)	36 318 (8 881)	43 084 (15 111)	36 087 (8 244)

	Pooled		ATBC³¹		HPFS³⁰
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	493	978	46	92	29	58
Mean age at blood draw, y (SD)	63.3 (7.1)	63.3 (7.2)	58.6 (4.7)	58.5 (4.7)	62.7 (9.4)	62.6 (9.5)
Sex, N (%)
Male	172 (34.9)	344 (35.2)	46 (100)	92 (100)	29 (100)	58 (100)
Female	321 (65.1)	634 (64.8)	NA	NA	NA	NA
Race, N (%)
White	432 (87.6)	860 (87.9)	46 (100)	92 (100)	26 (89.7)	55 (94.8)
Black	32 (6.5)	62 (5.3)	NA	NA	1 (3.5)	NA
Asian	12 (2.4)	25 (2.6)	NA	NA	NA	NA
Other	17 (3.4)	31 (3.2)	NA	NA	2 (6.9)	3 (5.2)
Mean BMI at blood draw, kg/m² (SD)	27.4 (5.2)	27.2 (5.0)	26.7 (2.8)	26.2 (3.8)	26.3 (3.3)	26.0 (3.2)
<18.5, N (%)	2 (0.4)	8 (0.8)	NA	NA	9 (31.0)	24 (41.4)
18.5-<25, N (%)	163 (33.1)	342 (35.0)	10 (21.7)	37 (40.2)	15 (51.7)	27 (46.6)
25-<30, N (%)	215 (43.6)	406 (41.5)	29 (63.0)	42 (45.7)	4 (13.8)	4 (6.9)
30+, N (%)	110 (22.3)	212 (21.7)	7 (15.2)	13 (14.1)	1 (3.5)	3 (5.2)
Missing, N (%)	3 (0.6)	10 (1.0)	NA	NA	NA	NA
Type of blood sample, N (%)
Serum	70 (14.2)	140 (14.3)	46 (100)	92 (100)	NA	NA
Plasma, heparin	200 (40.6)	392 (40.1)	NA	NA	NA	NA
Plasma, EDTA	202 (41.0)	404 (41.3)	NA	NA	29 (100)	58 (100)
Plasma, sodium citrate	21 (4.3)	42 (4.3)	NA	NA	NA	NA
Fasting status, N (%)
Fasting	354 (71.8)	709 (72.5)	39 (84.8)	78 (84.8)	21 (72.4)	42 (72.4)
Not fasting	139 (28.2)	269 (27.5)	7 (15.2)	14 (15.2)	8 (27.6)	16 (27.6)
Mean blood draw to diagnosis, y (range)	6.6 (0.3-18.1)	6.5 (−0.5 to 18.2)	9.8 (1.3-18.1)	9.8 (1.3-18.2)	6.6 (0.5-12.2)	6.6 (0.4-12.3)
≤3, N (%)	92 (18.7)	170 (17.9)	4 (8.7)	8 (8.7)	8 (28.6)	15 (27.3)
4-≤6, N (%)	150 (30.6)	303 (31.8)	10 (21.7)	18 (19.6)	5 (17.9)	10 (18.2)
>6, N (%)	249 (50.7)	479 (50.3)	32 (69.6)	66 (71.7)	15 (53.6)	30 (54.6)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	150 (52.5)	146.4 (49.4)	170.3 (38.7)	150.9 (44.5)	189.6 (49.2)	168.8 (46.2)
IGFBP-3, ng/mL	4 490 (1 203)	4 423 (1 170)	3 859 (941)	3 402 (1 053)	4 531 (1 110)	4 267 (991)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.2 (0.04)	0.2 (0.03)	0.2 (0.03)	0.1 (0.02)
IGFBP-1, ng/mL	32.2 (24.9)	30.3 (32.3)	21.9 (14.9)	25.2 (14.7)	34.9 (29.5)	28.8 (19.9)
C-peptide, ng/mL	2.1 (1.5)	2.1 (1.6)	1.9 (0.8)	1.7 (1.1)	2.4 (1.1)	2.6 (1.6)
CRP, mg/L	3.5 (5.6)	3.7 (5.8)	4.1 (6.8)	4.2 (8.3)	1.7 (1.6)	1.3 (1.4)
IL-6, pg/mL	2.2 (2.3)	2.5 (4.5)	3.0 (2.9)	3.7 (5.5)	1.7 (1.5)	1.5 (1.2)
sIL6R, pg/mL	41 871 (15 713)	39 278 (10 923)	36 502 (9 674)	36 318 (8 881)	43 084 (15 111)	36 087 (8 244)

Percentages and counts may not sum to the total because of rounding and/or missing data.

NA indicates not applicable.

Table 2

Selected characteristics of the study population by cohort (MCCS, NHS, and PLCO)

	MCCS²³		NHS^22,25		PLCO²⁶
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	55	110	39	71	96	192
Mean age at blood draw, y (SD)	59.5 (7.4)	59.5 (7.4)	59.4 (6.0)	58.3 (5.9)	63.9 (5.2)	63.8 (5.0)
Sex, N (%)
Male	31 (56.4)	62 (56.4)	NA	NA	60 (62.5)	120 (62.5)
Female	24 (43.6)	48 (43.6)	39 (100)	71 (100)	36 (37.5)	72 (37.5)
Race, N (%)
White	55 (100)	110 (100)	39 (100)	71 (100)	87 (90.6)	174 (90.6)
Black	NA	NA	NA	NA	4 (4.2)	8 (4.2)
Asian	NA	NA	NA	NA	2 (2.1)	4 (2.1)
Other	NA	NA	NA	NA	3 (3.1)	6 (3.1)
Mean BMI at blood draw, kg/m² (SD)	27.4 (4.2)	26.8 (3.9)	26.1 (4.7)	25.4 (4.5)	28.4 (6.0)	27.5 (4.7)
<18.5, N (%)	1 (1.8)	NA	1 (2.6)	NA	NA	2 (1.0)
18.5-<25, N (%)	16 (29.1)	38 (34.6)	16 (41.0)	36 (50.7)	27 (28.1)	53 (27.6)
25-<30, N (%)	24 (43.6)	50 (45.5)	14 (35.9)	20 (28.2)	41 (42.7)	95 (49.5)
30+, N (%)	14 (25.5)	22 (20.0)	6 (15.4)	10 (14.1)	28 (29.2)	40 (20.8)
Missing, N (%)	NA	NA	2 (5.1)	5 (7.0)	NA	2 (1.0)
Type of blood sample, N (%)
Serum	NA	NA	NA	NA	NA	NA
Plasma, heparin	55 (100)	110 (100)	39 (100)	71 (100)	96 (100)	192 (100)
Plasma, EDTA	NA	NA	NA	NA	NA	NA
Plasma, sodium citrate	NA	NA	NA	NA	NA	NA
Fasting status, N (%)
Fasting	42 (76.4)	84 (76.4)	27 (69.2)	56 (78.9)	NA	NA
Not fasting	13 (23.6)	26 (23.6)	12 (30.8)	15 (21.1)	96 (100)	193 (100)
Mean blood draw to diagnosis, y (range)	8.2 (1.1-16.8)	8.2 (1.2-16.8)	9.4 (1.5-16.0)	9.8 (2.8-16.1)	6.4 (1.2-12.3)	6.4 (1.2-12.5)
≤3, N (%)	6 (10.9)	10 (9.1)	2 (5.3)	1 (1.9)	9 (9.4)	17 (8.9)
4-≤6, N (%)	14 (25.5)	30 (27.3)	6 (15.8)	10 (18.9)	37 (38.5)	75 (39.1)
>6, N (%)	35 (63.6)	70 (63.6)	30 (79.0)	42 (79.3)	50 (52.1)	100 (52.1)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	158.9 (52.9)	161.5 (50.2)	151.5 (51.2)	151.3 (47.4)	159.9 (58.5)	158.1 (52.0)
IGFBP-3, ng/mL	4 777 (1 404)	4 872 (1 170)	5 300 (1 299)	5 327 (1 293)	4 708 (1 285)	4 660 (1 069)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.1 (0.02)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)
IGFBP-1, ng/mL	34.4 (23.6)	25.4 (15.2)	20.9 (13.1)	24.4 (15.4)	N/A	N/A
C-peptide, ng/mL	1.7 (1.2)	1.5 (0.8)	2.2 (1.4)	2.5 (1.7)	2.8 (1.8)	3.0 (2.5)
CRP, mg/L	3.1 (7.8)	2.3 (3.0)	2.6 (3.8)	2.8 (3.9)	3.4 (4.8)	3.7 (6.0)
IL-6, pg/mL	1.7 (1.4)	2.4 (3.6)	2.2 (2.9)	1.6 (1.5)	2.3 (1.7)	2.4 (2.3)
sIL6R, pg/mL	42 252 (11 293)	41 908 (10 234)	42 793 (10 563)	40 909 (10 879)	43 495 (11 683)	41 909 (10 816)

	MCCS²³		NHS^22,25		PLCO²⁶
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	55	110	39	71	96	192
Mean age at blood draw, y (SD)	59.5 (7.4)	59.5 (7.4)	59.4 (6.0)	58.3 (5.9)	63.9 (5.2)	63.8 (5.0)
Sex, N (%)
Male	31 (56.4)	62 (56.4)	NA	NA	60 (62.5)	120 (62.5)
Female	24 (43.6)	48 (43.6)	39 (100)	71 (100)	36 (37.5)	72 (37.5)
Race, N (%)
White	55 (100)	110 (100)	39 (100)	71 (100)	87 (90.6)	174 (90.6)
Black	NA	NA	NA	NA	4 (4.2)	8 (4.2)
Asian	NA	NA	NA	NA	2 (2.1)	4 (2.1)
Other	NA	NA	NA	NA	3 (3.1)	6 (3.1)
Mean BMI at blood draw, kg/m² (SD)	27.4 (4.2)	26.8 (3.9)	26.1 (4.7)	25.4 (4.5)	28.4 (6.0)	27.5 (4.7)
<18.5, N (%)	1 (1.8)	NA	1 (2.6)	NA	NA	2 (1.0)
18.5-<25, N (%)	16 (29.1)	38 (34.6)	16 (41.0)	36 (50.7)	27 (28.1)	53 (27.6)
25-<30, N (%)	24 (43.6)	50 (45.5)	14 (35.9)	20 (28.2)	41 (42.7)	95 (49.5)
30+, N (%)	14 (25.5)	22 (20.0)	6 (15.4)	10 (14.1)	28 (29.2)	40 (20.8)
Missing, N (%)	NA	NA	2 (5.1)	5 (7.0)	NA	2 (1.0)
Type of blood sample, N (%)
Serum	NA	NA	NA	NA	NA	NA
Plasma, heparin	55 (100)	110 (100)	39 (100)	71 (100)	96 (100)	192 (100)
Plasma, EDTA	NA	NA	NA	NA	NA	NA
Plasma, sodium citrate	NA	NA	NA	NA	NA	NA
Fasting status, N (%)
Fasting	42 (76.4)	84 (76.4)	27 (69.2)	56 (78.9)	NA	NA
Not fasting	13 (23.6)	26 (23.6)	12 (30.8)	15 (21.1)	96 (100)	193 (100)
Mean blood draw to diagnosis, y (range)	8.2 (1.1-16.8)	8.2 (1.2-16.8)	9.4 (1.5-16.0)	9.8 (2.8-16.1)	6.4 (1.2-12.3)	6.4 (1.2-12.5)
≤3, N (%)	6 (10.9)	10 (9.1)	2 (5.3)	1 (1.9)	9 (9.4)	17 (8.9)
4-≤6, N (%)	14 (25.5)	30 (27.3)	6 (15.8)	10 (18.9)	37 (38.5)	75 (39.1)
>6, N (%)	35 (63.6)	70 (63.6)	30 (79.0)	42 (79.3)	50 (52.1)	100 (52.1)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	158.9 (52.9)	161.5 (50.2)	151.5 (51.2)	151.3 (47.4)	159.9 (58.5)	158.1 (52.0)
IGFBP-3, ng/mL	4 777 (1 404)	4 872 (1 170)	5 300 (1 299)	5 327 (1 293)	4 708 (1 285)	4 660 (1 069)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.1 (0.02)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)
IGFBP-1, ng/mL	34.4 (23.6)	25.4 (15.2)	20.9 (13.1)	24.4 (15.4)	N/A	N/A
C-peptide, ng/mL	1.7 (1.2)	1.5 (0.8)	2.2 (1.4)	2.5 (1.7)	2.8 (1.8)	3.0 (2.5)
CRP, mg/L	3.1 (7.8)	2.3 (3.0)	2.6 (3.8)	2.8 (3.9)	3.4 (4.8)	3.7 (6.0)
IL-6, pg/mL	1.7 (1.4)	2.4 (3.6)	2.2 (2.9)	1.6 (1.5)	2.3 (1.7)	2.4 (2.3)
sIL6R, pg/mL	42 252 (11 293)	41 908 (10 234)	42 793 (10 563)	40 909 (10 879)	43 495 (11 683)	41 909 (10 816)

Percentages and counts may not sum to the total because of rounding and/or missing data.

NA indicates not applicable.

Table 3

Selected characteristics of the study population by cohort (SCHS, WHI, and WHS)

	SCHS^24,27		WHI³²		WHS²⁹
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	10	19	197	394	21	42
Mean age at blood draw, y (SD)	66.5 (6.6)	66.4 (6.7)	66.4 (6.5)	66.5 (6.5)	58.7 (6.9)	58.6 (6.7)
Sex, N (%)
Male	6 (60.0)	12 (63.2)	NA	NA	NA	NA
Female	4 (40.0)	7 (36.8)	197 (100)	394 (100)	21 (100)	42 (100)
Race, N (%)
White	NA	NA	160 (81.2)	320 (81.2)	19 (90.5)	38 (90.5)
Black	NA	NA	26 (13.2)	52 (13.2)	1 (4.8)	2 (4.8)
Asian	10 (100)	19 (100)	NA	NA	NA	2 (4.8)
Other	NA	NA	11 (5.6)	22 (5.6)	1 (4.8)	NA
Mean BMI at blood draw, kg/m² (SD)	23.7 (2.6)	23 (3.0)	27.8 (5.7)	28.2 (5.7)	25.7 (4.1)	26.6 (4.4)
<18.5, N (%)	NA	2 (10.5)	NA	4 (1.0)	NA	NA
18.5-<25, N (%)	8 (80.0)	11 (57.9)	66 (33.5)	128 (32.5)	11 (52.4)	15 (35.7)
25-<30, N (%)	2 (20.0)	6 (31.6)	82 (41.6)	146 (37.1)	8 (38.1)	20 (47.6)
30+, N (%)	NA	NA	49 (24.9)	116 (29.4)	2 (9.5)	7 (16.7)
Missing, N (%)	NA	NA	NA	NA	NA	NA
Type of blood sample, N (%)
Serum	NA	NA	24 (12.2)	48 (12.2)	NA	NA
Plasma, heparin	10 (100)	19 (100)	NA	NA	NA	NA
Plasma, EDTA	NA	NA	173 (87.8)	346 (87.8)	NA	NA
Plasma, sodium citrate	NA	NA	NA	NA	21 (100)	42 (100)
Fasting status, N (%)
Fasting	10 (100)	19 (100)	197 (100)	394 (100)	18 (85.7)	36 (85.7)
Not fasting	NA	NA	NA	NA	3 (14.3)	6 (14.3)
Mean blood draw to diagnosis, y (range)	2.5 (0.3-5.2)	2.5 (0.2-5.1)	5.2 (0.5-11.1)	5.2 (-0.5-11.3)	6.1 (2.2-9.8)	6.1 (2.2-9.8)
≤3, N (%)	6 (60.0)	11 (57.9)	51 (25.9)	98 (25.2)	6 (28.6)	10 (23.8)
4-≤6, N (%)	4 (40.0)	8 (42.1)	69 (35.0)	140 (36.0)	5 (23.8)	12 (28.6)
>6, N (%)	NA	NA	77 (39.1)	151 (38.8)	10 (47.6)	20 (47.6)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	136.2 (43.9)	133.2 (44.1)	136.5 (48.5)	133.2 (46.7)	112.4 (31.4)	134.7 (43.5)
IGFBP-3, ng/mL	4 456 (1 213)	4 356 (1 427)	4 356 (1 059)	4 313 (1 046)	3 825 (744)	4 152 (901)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)
IGFBP-1, ng/mL	71.0 (47.0)	64.0 (137.9)	33.2 (24.7)	32.0 (26.6)	31.0 (14.6)	28.2 (26.3)
C-peptide, ng/mL	5.7 (5.6)	5.1 (2.2)	1.7 (0.8)	1.7 (0.8)	2.0 (1.1)	2.1 (1.1)
CRP, mg/L	1.0 (1.2)	1.2 (1.9)	3.9 (5.3)	4.5 (6.4)	4.7 (8.7)	3.7 (4.8)
IL-6, pg/mL	2.4 (2.1)	1.9 (2.0)	2.2 (2.6)	2.7 (5.8)	NA	NA
sIL6R, pg/mL	65 025 (70 369)	30 364 (6 864)	40 665 (12 232)	38 537 (11 544)	NA	NA

	SCHS^24,27		WHI³²		WHS²⁹
	Cases	Controls	Cases	Controls	Cases	Controls
No. of persons	10	19	197	394	21	42
Mean age at blood draw, y (SD)	66.5 (6.6)	66.4 (6.7)	66.4 (6.5)	66.5 (6.5)	58.7 (6.9)	58.6 (6.7)
Sex, N (%)
Male	6 (60.0)	12 (63.2)	NA	NA	NA	NA
Female	4 (40.0)	7 (36.8)	197 (100)	394 (100)	21 (100)	42 (100)
Race, N (%)
White	NA	NA	160 (81.2)	320 (81.2)	19 (90.5)	38 (90.5)
Black	NA	NA	26 (13.2)	52 (13.2)	1 (4.8)	2 (4.8)
Asian	10 (100)	19 (100)	NA	NA	NA	2 (4.8)
Other	NA	NA	11 (5.6)	22 (5.6)	1 (4.8)	NA
Mean BMI at blood draw, kg/m² (SD)	23.7 (2.6)	23 (3.0)	27.8 (5.7)	28.2 (5.7)	25.7 (4.1)	26.6 (4.4)
<18.5, N (%)	NA	2 (10.5)	NA	4 (1.0)	NA	NA
18.5-<25, N (%)	8 (80.0)	11 (57.9)	66 (33.5)	128 (32.5)	11 (52.4)	15 (35.7)
25-<30, N (%)	2 (20.0)	6 (31.6)	82 (41.6)	146 (37.1)	8 (38.1)	20 (47.6)
30+, N (%)	NA	NA	49 (24.9)	116 (29.4)	2 (9.5)	7 (16.7)
Missing, N (%)	NA	NA	NA	NA	NA	NA
Type of blood sample, N (%)
Serum	NA	NA	24 (12.2)	48 (12.2)	NA	NA
Plasma, heparin	10 (100)	19 (100)	NA	NA	NA	NA
Plasma, EDTA	NA	NA	173 (87.8)	346 (87.8)	NA	NA
Plasma, sodium citrate	NA	NA	NA	NA	21 (100)	42 (100)
Fasting status, N (%)
Fasting	10 (100)	19 (100)	197 (100)	394 (100)	18 (85.7)	36 (85.7)
Not fasting	NA	NA	NA	NA	3 (14.3)	6 (14.3)
Mean blood draw to diagnosis, y (range)	2.5 (0.3-5.2)	2.5 (0.2-5.1)	5.2 (0.5-11.1)	5.2 (-0.5-11.3)	6.1 (2.2-9.8)	6.1 (2.2-9.8)
≤3, N (%)	6 (60.0)	11 (57.9)	51 (25.9)	98 (25.2)	6 (28.6)	10 (23.8)
4-≤6, N (%)	4 (40.0)	8 (42.1)	69 (35.0)	140 (36.0)	5 (23.8)	12 (28.6)
>6, N (%)	NA	NA	77 (39.1)	151 (38.8)	10 (47.6)	20 (47.6)
Mean peripheral blood biomarker concentrations (SD)
IGF-1, ng/mL	136.2 (43.9)	133.2 (44.1)	136.5 (48.5)	133.2 (46.7)	112.4 (31.4)	134.7 (43.5)
IGFBP-3, ng/mL	4 456 (1 213)	4 356 (1 427)	4 356 (1 059)	4 313 (1 046)	3 825 (744)	4 152 (901)
IGF-1/IGFBP-3 molar ratio	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)	0.1 (0.03)
IGFBP-1, ng/mL	71.0 (47.0)	64.0 (137.9)	33.2 (24.7)	32.0 (26.6)	31.0 (14.6)	28.2 (26.3)
C-peptide, ng/mL	5.7 (5.6)	5.1 (2.2)	1.7 (0.8)	1.7 (0.8)	2.0 (1.1)	2.1 (1.1)
CRP, mg/L	1.0 (1.2)	1.2 (1.9)	3.9 (5.3)	4.5 (6.4)	4.7 (8.7)	3.7 (4.8)
IL-6, pg/mL	2.4 (2.1)	1.9 (2.0)	2.2 (2.6)	2.7 (5.8)	NA	NA
sIL6R, pg/mL	65 025 (70 369)	30 364 (6 864)	40 665 (12 232)	38 537 (11 544)	NA	NA

Percentages and counts may not sum to the total because of rounding and/or missing data.

NA indicates not applicable.

Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012;120(25):4929-4937.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012;120(25):4929-4937.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only